Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization

被引:39
作者
Querol-Ribelles, JM
Tenías, JM
Querol-Borrás, JM
Labrador, T
Nieto, A
González-Granda, D
Martínez, I
机构
[1] Hosp Lluis Alcanyis, Internal Med Serv, Xativa 46800, Spain
[2] Hosp Lluis Alcanyis, Prevent Med Serv, Xativa 46800, Spain
[3] Hosp Lluis Alcanyis, Microbiol Serv, Xativa 46800, Spain
关键词
community-acquired pneumonia; levofloxacin; clarithromycin; ceftriaxone; mortality;
D O I
10.1016/j.ijantimicag.2004.07.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500 mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2 2 once a day and 500 mg every 12 h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group created with ceftriaxone plus clarithromycin (P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17-0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All fights reserved.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 40 条
  • [1] Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia
    Anderson, KB
    Tan, JS
    File, TM
    DiPersio, JR
    Willey, BM
    Low, DE
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) : 376 - 381
  • [2] Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
  • [3] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [4] Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia
    Clark, LC
    Davis, CW
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (22) : S10 - S13
  • [5] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Davidson, R
    Cavalcanti, R
    Brunton, JL
    Bast, DJ
    de Azavedo, JCS
    Kibsey, P
    Fleming, C
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) : 747 - 750
  • [6] Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
    Doern, GV
    Heilmann, KP
    Huynh, HK
    Rhomberg, PR
    Coffman, SL
    Brueggemann, AB
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1721 - 1729
  • [7] Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals
    Dudas, V
    Hopefl, A
    Jacobs, R
    Guglielmo, BJ
    [J]. ANNALS OF PHARMACOTHERAPY, 2000, 34 (04) : 446 - 452
  • [8] High-dose, short-course Levofloxacin for community-acquired pneumonia: A new treatment paradigm
    Dunbar, LM
    Wunderink, RG
    Habib, MP
    Smith, LG
    Tennenberg, AM
    Khashab, MM
    Wiesinger, BA
    Xiang, JX
    Zadeikis, N
    Kahn, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 752 - 760
  • [9] A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
    File, TM
    Segreti, J
    Dunbar, L
    Player, R
    Kohler, R
    Williams, RR
    Kojak, C
    Rubin, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 1965 - 1972
  • [10] Prognosis and outcomes of patients with community-acquired pneumonia - A meta-analysis
    Fine, MJ
    Smith, MA
    Carson, CA
    Mutha, SS
    Sankey, SS
    Weissfeld, LA
    Kapoor, WN
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02): : 134 - 141